Canthevac, a start-up established in 2024, is the subsidiary of Hong Kong Universal Vaccine (HKUV) spun off from the Centre for Virology, Vaccinology, and Therapeutics (CVVT) and The University of Hong Kong. We specialize in the development of novel vaccines and cancer therapeutics. By integrating immunotherapy, AI-driven structure-guided protein design, bioinformatics, microfluidics, live-attenuated viral vector, and lipid nanoparticle technology, our company has successfully established a comprehensive framework for creating vaccines for infectious diseases and cancers. This ground-breaking platform utilizes live-attenuated viral vectors, lipid nanoparticles, and mRNA encoding AI-based structure-guided neoantigens, enabling the further development of highly effective therapeutic vaccines targeting pancreatic, colorectal, and non-small cell lung cancers.